Second-line Maintenance Therapy in Ovarian Cancer: PARP Inhibitors

Bhavesh Shah, RPh, BCOP, provides a brief history of PARP inhibitors in the cancer space, as well as his own introduction to PARP inhibitors.

Bhavesh Shah, RPh, BCOP; and Thomasina Morris, RPh, MHA, BCOP, discuss the mechanism of action and efficacy for the 3 PARP inhibitors used to treat patients with ovarian cancer: olaparib, rucaparib, and niraparib.

Two board-certified oncology pharmacists review the importance of PARP inhibitors for second-line maintenance in treating ovarian cancer.

Bhavesh Shah, RPh, BCOP; and Thomasina Morris, RPh, MHA, BCOP, detail what makes a patient eligible to receive PARP inhibitors as second-line maintenance for the management of ovarian cancer.

Bhavesh Shah, RPh, BCOP, reviews data and results from the ARIEL3 trial that studied the PARP inhibitor, rucaparib, for the management of ovarian cancer.

Bhavesh Shah, RPh, BCOP, and Thomasina Morris, RPh, MHA, BCOP, discuss toxicities to monitor for when using PARP inhibitors to battle ovarian cancer.

Board-certified oncology pharmacists Bhavesh Shah, RPh, BCOP; and Thomasina Morris, RPh, MHA, BCOP, talk about exciting ongoing PARP inhibitor research concerning ovarian cancer.

Bhavesh Shah, RPh, BCOP; and Thomasina Morris, RPh, MHA, BCOP, delve into the challenges faced with using PARP inhibitors as second-line maintenance therapy for the treatment of ovarian cancer.